The launch triggered a $2.5m final EU milestone payment to BDSI, which will also receive royalty payments on the sales of Breakyl in the EU.
The drug is being launched in selective European countries in 2012, including Germany, and is further expected to be introduced in most EU countries throughout 2013.
Meda’s US affiliate, Meda Pharmaceuticals, has commercialized Breakyl as Onsolis (fentanyl buccal soluble film) in the US.
The drug is indicated for the pain management in cancer patients already receiving and tolerant to opioid therapy for their underlying persistent cancer pain.